|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | GIS在环保型养猪业区域规划中的应用显示文摘快速发展的养猪业在带来巨大社会效益和经济效益的同时也带来了许多环境问题,FAO从1998年开始启动了养殖业环境与发展项目,目的是为了在促进养殖业发展、增加经济效益的同时大幅度减少养殖业对环境的不利影响。该文是FAO项目中的一部分,主要是应用G IS技术工具,通过建立养猪业选址的指标体系,发展了可持续的畜牧业生产建设区域规划的决策辅助工具,以减少养猪业发展对环境带来的负面影响;并且将该技术在江西省的养猪大县万年县进行了具体的应用。 | 赵小敏 Gerrit J Carsjens Pierre Gerber | 2006 | 农业工程学报2006，22，9： | 12 |
| 2 | Challenges and prospects for consumer acceptance of cultured meat显示文摘Consumer acceptance of cultured meat is expected to depend on a wide diversity of determinants ranging from technologyrelated perceptions to product-specific expectations, and including wider contextual factors like media coverage, public involvement, and trust in science, policy and society. This paper discusses the case of cultured meat against this multitude of possible determinants shaping future consumer acceptance or rejection. The paper also presents insights from a primary exploratory study performed in April 2013 with consumers from Flanders(Belgium)(n=180). The concept of cultured meat was only known(unaided) by 13% of the study participants. After receiving basic information about what cultured meat is, participants expressed favorable expectations about the concept. Only 9% rejected the idea of trying cultured meat, while two thirds hesitated and about quarter indicated to be willing to try it. The provision of additional information about the environmental benefits of cultured meat compared to traditional meat resulted in 43% of the participants indicating to be willing to try this novel food, while another 51% indicated to be ‘maybe' willing to do so. Price and sensory expectations emerged as major obstacles. Consumers eating mostly vegetarian meals were less convinced that cultured meat might be healthy, suggesting that vegetarians may not be the ideal primary target group for this novel meat substitute. Although exploratory rather than conclusive, the findings generally underscore doubts among consumers about trying this product when it would become available, and therefore also the challenge for cultured meat to mimic traditional meat in terms of sensory quality at an affordable price in order to become acceptable for future consumers. | Wim Verbeke Pierre Sans Ellen J Van Loo | 2015 | Journal of Integrative Agriculture2015，14，2： | 10 |
| 3 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet . 2005 (9472)2005，，9472： | 6 |
| 4 | Biomarkers in Barrett's esophagus and esophageal adenocarcinoma:Predictors of progression and prognosis显示文摘Barrett’s esophagus is a well-known premalignant lesion of the lower esophagus that is characterized by intestinal metaplasia of the squamous epithelium. It is clinically important due to the increased risk (0.5% per annum) of progression to esophageal adenocarcinoma (EA), which has a poor outcome unless diagnosed early. The current clinical management of Barrett’s esophagus is hampered by the lack of accurate predictors of progression. In addition, when patients develop EA, the current staging modalities are limited in stratifying patients into different prognostic groups in order to guide the optimal therapy for an individual patient. Biomarkers have the potential to improve radically the clinical management of patients with Barrett’s esophagus and EA but have not yet entered mainstream clinical practice. This is in contrast to other cancers like breast and prostate for which biomarkers are utilized routinely to inform clinical decisions. This review aims to highlight the most promising predictive and prognostic biomarkers in Barrett’s esophagus and EA and to discuss what is required to move the field forward towards clinical application. | Chin-Ann J Ong Pierre Lao-Sirieix Rebecca C Fitzgerald | 2010 | World Journal of Gastroenterology2010，16，45： | 6 |
| 5 | Management of digestive bleeding related to portal hypertension in cirrhotic patients:A French multicenter cross-sectional practice survey显示文摘AIM: To investigate the conformity of management practices of gastrointestinal hemorrhage in cirrhotic patients with relevant guidelines. METHODS: A questionnaire on the management of digestive bleeding was completed for all consecutive cirrhotic patients admitted to 31 French hospitals. RESULTS: One hundred and twenty-six bleeding events were recorded. It was the first bleeding episode in 79 patients (63%), of whom 40 (51%) had a prior diagnosis of cirrhosis and 25 (32%) had previously undergone an endoscopy. The bleeding episode was a recurrence in 46 patients (37%). The median time between onset and admission was 4 h, but exceeded 12 h in 42% of cases. There was an agreement between centers forearly vasoactive drug administration (87% of cases), association with ligation (42%) more often than sclerosis (21%) at initial endoscopy, and antibiotic prophylaxis (64%). By contrast, prescription of beta-blockade alone or in combination (0 to 100%, P = 0.003) for secondary prophylaxis and lactulose (26% to 86%, P = 0.04), differed among centers. CONCLUSION: In French hospitals, management of bleeding related to portal hypertension in cirrhotic patients is generally in keeping with the consensus. Broad variability still remains concerning beta-blockade use for secondary prophylaxis. Screening for esophageal varices, the use of antibiotic prophylaxis and patients information need to be improved. | Pierre Ingrand Jérme Gournay Pierre Bernard Frédéric Oberti Brigitte Bernard-Chabert Arnault Pauwels Philippe Renard Eric Bartoli Jean-Franois Cadranel Jean-Claude Barbare Isabelle Ingrand Michel Beauchant | 2006 | World Journal of Gastroenterology2006，12，48： | 4 |
| 6 | Endoscopic ultrasound-guided drainage of the biliary system:Techniques,indications and future perspectives显示文摘Over the last decade, endoscopic ultrasound-guided biliary drainage(EUS-BD)has evolved into a widely accepted alternative to the percutaneous approach in cases of biliary obstruction with failed endoscopic retrograde cholangiopancreaticography(ERCP). The available evidence suggests that, in experienced hands, EUS-BD might even replace ERCP as the first-line procedure in specific situations such as malignant distal bile duct obstruction. The aim of this review is to summarize the available data on EUS-BD and propose an evidence-based algorithm clarifies the role of the different EUS-BD techniques in the management of benign and malignant biliary obstructive disease. | Pieter Hindryckx Helena Degroote David J Tate Pierre H Deprez | 2019 | World Journal of Gastrointestinal Endoscopy2019，11，2： | 4 |
| 7 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet2005，，9472： | 4 |
| 8 | MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer显示文摘Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma(PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients(80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are des-perately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC. | Marion Gayral Sébastien Jo Naima Hanoun Alix Vignolle-Vidoni Hubert Lulka Yannick Delpu Aline Meulle Marlène Dufresne Marine Humeau Maёl Chalret du Rieu Barbara Bournet Janick Sèlves Rosine Guimbaud Nicolas Carrère Louis Buscail Jérome Torrisani Pierre Cordelier | 2014 | World Journal of Gastroenterology2014，20，32： | 4 |
| 9 | ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction显示文摘 | Eugene Braunwald Elliott M Antman John W Beasley Robert M Califf Melvin D Cheitlin Judith S Hochman Robert H Jones Dean Kereiakes Joel Kupersmith Thomas N Levin Carl J Pepine John W Schaeffer Earl E Smith David E Steward Pierre Theroux Raymond J Gibbons J | 2000 | Journal of the American College of Cardiology2000，，3： | 4 |
| 10 | Endoscopy-based management decreases the risk of postoperative recurrences in Crohn's disease显示文摘AIM: To investigate whether an endoscopy-based management could prevent the long-term risk of postoperative recurrence.METHODS: From the pathology department database, we retrospectively retrieved the data of all the patients operated on for Crohn's disease(CD) in our center(1986-2015). Endoscopy-based management was defined as systematic postoperative colonoscopy(median time after surgery = 9.5 mo) in patients with no clinical postoperative recurrence at the time of endoscopy. RESULTS: From 205 patients who underwent surgery, 161 patients(follow-up > 6 mo) were included. Endoscopic postoperative recurrence occurred in 67.6%, 79.7%, and 95.5% of the patients, respectively 5, 10 and 20 years after surgery. The rate of clinical postoperative recurrence was 61.4%, 75.9%, and 92.5% at 5, 10 and 20 years, respectively. The rate of surgical postoperative recurrence was 19.0%, 38.9% and 64.7%, respectively, 5, 10 and 20 years after surgery. In multivariate analysis, previous intestinal resection, prior exposure to anti-TNF therapy before surgery, and fistulizing phenotype(B3) were postoperative risk factors. Previous perianal abscess/fistula(other perianal lesions excluded), were predictive of only symptomatic recurrence. In multivariate analysis, an endoscopy-based management(n = 49/161) prevented clinical(HR = 0.4, 95%CI: 0.25-0.66, P < 0.001) and surgical postoperative recurrence(HR = 0.30, 95%CI: 0.13-0.70, P = 0.006).CONCLUSION: Endoscopy-based management should be recommended in all CD patients within the first year after surgery as it highly decreases the long-term risk of clinical recurrence and reoperation. | Anne-Laure Boucher Bruno Pereira Stéphanie Decousus Marion Goutte Felix Goutorbe Anne Dubois Johan Gagniere Corinne Borderon Juliette Joubert Denis Pezet Michel Dapoigny Pierre J Déchelotte Gilles Bommelaer Anthony Buisson | 2016 | World Journal of Gastroenterology2016，22，21： | 3 |
| 11 | Ribavirin:Past,present and future显示文摘Before the advent of direct acting antiviral agents(DAAs) ribavirin, associated to pegylated-interferon played a crucial role in the treatment of chronic hepatitis C, preventing relapses and breakthroughs. In the present era of new potent DAAs, a place is still devoted to the drug. Ribavirin associated with sofosbuvir alone is efficient in the treatment of most cases of G2 infected patients. All options currently available for the last difficult-to-treat cirrhotic G3 patients contain ribavirin. Reducing treatment duration to 12 wk in G1 or G4 cirrhotic compensated patients is feasible thanks to ribavirin. Retreating patients with acquired anti NS5 A resistance-associated variants using ribavirin-based strategies could be useful. The addition of ribavirin with DAAs combinations however, leads to more frequent but mild adverse events especially in cirrhotic patients. Preliminary data with interferon-free second generation DAAs combinations without ribavirin suggest that future of the drug is jeopardized even in difficult-totreat patients: The optimization of ribavirin dosage according to an early monitoring of blood levels has been suggested to be relevant in double therapy with peginterferon or sofosbuvir but not with very potent combinations of more than two DAAs. | Véronique Loustaud-Ratti Marilyne Debette-Gratien Jérémie Jacques Sophie Alain Pierre Marquet DenisSautereau Annick Rousseau Paul Carrier | 2016 | World Journal of Hepatology2016，8，2： | 3 |
| 12 | Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer显示文摘Pancreatic ductal adenocarcinoma remains one of the most deadly types of tumor. Endoscopic ultrasoundguided fine-needle aspiration(EUS-FNA) is a safe, cost-effective, and accurate technique for evaluating and staging pancreatic tumors. However, EUS-FNA may be inconclusive or doubtful in up to 20% of cases. This review underlines the clinical interest of the molecular analysis of samples obtained by EUS-FNA in assessing diagnosis or prognosis of pancreatic cancer, especially in locally advanced tumors. On EUS-FNA materials DNA, mRNA and miRNA can be extracted, amplified, quantified and subjected to methylation assay. Kras mutation assay, improves diagnosis of pancreatic cancer. When facing to clinical and radiological presentations of pseudo-tumorous chronic pancreatitis, wildtype Kras is evocative of benignity. Conversely, in front of a pancreatic mass suspected of malignancy, a mutated Kras is highly evocative of pancreatic adenocarci-noma. This strategy can reduce false-negative diagnoses, avoids the delay of making decisions and reduces loss of surgical resectability. Similar approaches are conducted using analysis of miRNA expression as well as Mucin or markers of invasion(S100P, S100A6, PLAT or PLAU). Beyond the diagnosis approach, the prediction of response to treatment can be also investigated form biomarkers expression within EUS-FNA materials. | Barbara Bournet Marion Gayral Jérme Torrisani Janick Selves Pierre Cordelier Louis Buscail | 2014 | World Journal of Gastroenterology2014，20，31： | 3 |
| 13 | Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis显示文摘AIM To confirm previous conclusions on Saccharomyces cerevisiae(S. cerevisiae) CNCM I-3856 for irritable bowel syndrome(IBS) management.METHODS An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal(GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve(AUC) and weekly means], responder status, and bowel movements(stool frequency and consistency). Statistical analyses were conducted in Intent to Treat(ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline('IBS-C ≥ 2 subpopulation').RESULTS S. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC(W5-W8)]with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group(P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group(P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit(a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder(reduction of 1 a.u. of abdominal pain/discomfort) compared with subjects in the Placebo group(P = 0.0240). At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as 'normal' compared to Placebo(respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003). Similar results were seen in the IBS-C ≥ 2 subpopulation(Active group: 3.14 ± 1.219 a.u. vs Placebo group: 2.59 ± 1.017 a.u., P = 0.0009).CONCLUSION This meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations. | Amélie Cayzeele-Decherf Fanny Pélerin Sébastien Leuillet Benoit Douillard Béatrice Housez Murielle Cazaubiel Gunnard K Jacobson Peter Jüsten Pierre Desreumaux | 2017 | World Journal of Gastroenterology2017，23，2： | 2 |
| 14 | Dried-leaf Artemisia annua: A practical malaria therapeutic for developing countries?显示文摘Artemisinin from the plant Artemisia annua(A. annua) L., and used as artemisinin combination therapy(ACT), is the current best therapeutic for treating malaria, a disease that hits children and adults especially in developing countries. Traditionally, A. annua was used by the Chinese as a tea to treat 'fever'. More recently, investigators have shown that tea infusions and oral consumption of the dried leaves of the plant have prophylactic and therapeutic efficacy. The presence of a complex matrix of chemicals within the leaves seems to enhance both the bioavailability and efficacy of artemisinin. Although about 1000-fold less potent than artemisinin in their antiplasmodial activity, these plant chemicals are mainly small molecules that include other artemisinic compounds, terpenes(mainly mono and sesqui), flavonoids, and polyphenolic acids. In addition, polysaccharide constituents of A. annua may enhance bioavailability of artemisinin. Rodent pharmacokinetics showed longer T? and T max and greater C max and AUC in Plasmodium chabaudi-infected mice treated with A. annua dried leaves than in healthy mice. Pharmacokinetics of deoxyartemisinin, a liver metabolite of artemisinin, was more inhibited in infected than in healthy mice. In healthy mice, artemisinin serum levels were > 40-fold greater in dried leaf fed mice than those fed with pure artemisinin. Human trial data showed that when delivered as dried leaves, 40-fold less artemisinin was required to obtain a therapeutic response compared to pure artemisinin. ACTs are still unaffordable for many malaria patients, and cost estimates for A. annua dried leaf tablet production are orders of magnitude less than for ACT, despite improvements in the production capacity. Considering that for > 2000 years this plant was used in traditional Chinese medicine for treatment of fever with no apparent appearance of artemisinin drug resistance, the evidence argues for inclusion of affordable A. annua dried leaf tablets into the arsenal of drugs to combat malaria and other artemisinin-susceptible diseases. | Pamela J Weathers Melissa Towler Ahmed Hassanali Pierre Lutgen Patrick Ogwang Engeu | 2014 | World Journal of Pharmacology2014，3，4： | 2 |
| 15 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | 2005 (9472)2005，，9472： | 2 |
| 16 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study显示文摘 | Pierre Fenaux Ghulam J Mufti Eva Hellstrom-Lindberg Valeria Santini Carlo Finelli Aristoteles Giagounidis Robert Schoch Norbert Gattermann Guillermo Sanz Alan List Steven D Gore John F Seymour John M Bennett John Byrd Jay Backstrom Linda Zimmerman David M | 2009 | Lancet Oncology2009，，： | 2 |
| 17 | HCV ‐associated B ‐cell non‐ H odgkin lymphomas and new direct antiviral agents显示文摘 | Paul Carrier Arnaud Jaccard Jérémie Jacques Tessa Tabouret Marilyne Debette‐Gratien Julie Abraham Laura Mesturoux Pierre Marquet Sophie Alain Denis Sautereau Marie Essig Véronique Loustaud‐Ratti | 2015 | Liver Int2015，，10： | 2 |
| 18 | Dynamic cooperative advertising in a channel显示文摘 | Steffen J?rgensen Simon Pierre Sigué Georges Zaccour | 2000 | Journal of Retailing2000，，1： | 2 |
| 19 | Aflatoxin Exposure and Viral Hepatitis in the Etiology of Liver Cirrhosis in The Gambia, West Africa显示文摘 | Kuniholm Mark H Lesi Olufunmilayo A Mendy Maimuna Akano Aliu O Sam Omar Hall Andrew J Whittle Hilton Bah Ebrima Goedert James J Hainaut Pierre Kirk Gregory D | 2008 | Environmental Health Perspectives2008，，11： | 2 |
| 20 | Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development显示文摘 | Philippe J Guerin Piero Olliaro Francois Nosten Pierre Druilhe Ramanan Laxminarayan Fred Binka Wen L Kilama Nathan Ford Nicholas J White | 2002 | The Lancet Infectious Diseases2002，，9： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员